Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2019

View Archived Issues

Meta-analysis reveals universally altered genes in early AD

New cholesterol target works independently of LDL receptor

Celyad opens enrollment in phase I trial of CYAD-1 for relapsed/refractory AML or MDS

Akari announces trial design for pivotal phase III study of nomacopan in pediatric HSCT-TMA

BiomX completes enrollment in cosmetic clinical study of BX-001 in acne-prone skin

Funding supports LUNAC-led project to develop next-generation anticoagulant

Neurocrine Biosciences and Xenon collaborate to develop first-in-class treatments for epilepsy

Noxopharm announces promising data from DARRT-1 study of Veyonda in prostate cancer

Seattle Genetics, Astellas, Merck & Co. collaborate to study enfortumab + Keytruda in bladder cancer

Phase IIa study of masupirdine in moderate Alzheimer's disease misses primary endpoint

Novel acute challenge mouse model to assess malaria T-cell vaccine antigens in mice

First report of a schistosome target activated by schistosomes

Phase II results for tislelizumab plus chemotherapy in GC/GEJC and ESCC

SHR-1210 plus apatinib as promising first-line treatment for advanced lung squamous carcinoma

Gilead identifies new Mcl-1 inhibitors

New Bruton tyrosine kinase inhibitors discovered at Biogen

Novo Nordisk patents melanocortin MC4 receptor agonists

Arbutus Biopharma discloses anti-HBV/HDV compounds

Nitric oxide production enhancers identified at Gurus Biopharm

One-year data reported for clinical trial of Pfs230D1M-EPA/AS01 malaria vaccination regimen

Enterotoxigenic E. coli vaccine Etvax in children and infants from Bangladesh: phase I/II results

Darobactin, new antibiotic against Gram-negative pathogens from Photorhabdus nematode symbionts

TAF1 is crucial for AML1-ETO-driven leukemogenesis

Dosing begins in phase I study of UCART-22 in relapsed/refractory B-ALL

OSE-127 phase I data pave way for phase II studies in ulcerative colitis and Sjogren's syndrome

NantKwest reports first safety data from phase I trial of PD-L1 t-haNK in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...